Impact of Probiotics on Neuropathy Induced by Adjuvant Chemotherapy in Patients With Colon Cancer.

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCentre Francois Baclesse

About this trial

The pbjective of this study is to assess the impact of a multi-strain bacteria probiotic OXXYSLAB® on the reduction of oxaliplatin-induced peripheral neuropathy in patients with stage III colon cancer receiving FOLFOX or XELOX regimen in adjuvant treatment, assessed using the oxaliplatin-specific scale of Levi.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patient ≥ 18 years

Patient with histologically confirmed stage III adenocarcinoma colon cancer with curative resection

Patient with an indication to start adjuvant oxaliplatin-based chemotherapy (FOLFOX 4 or XELOX regimen)

ECOG performance status score of 0 or 1

Disqualifiers

None

Trial design

Design model

Parallel

Treatments tested in this trial

  • PROBIOTIC SUPPLEMENTATION BY OXXYSLAB®

    Dietary supplement

    PROBIOTIC treatment (OXXYSLAB®) starts 1 week before first administration of chemotherapy (XELOX or FOLFOX) and be continued until 1 week after end of the last cycle of chemotherapy. PROBIOTIC treatment (OXXYSLAB®) is administered orally , in 1 daily dose.

  • PLACEBO supplementation

    Dietary supplement

    PLACEBO supplementation starts 1 week before first administration of chemotherapy (XELOX or FOLFOX) and be continued until 1 week after end of the last cycle of chemotherapy. PROBIOTIC treatment (OXXYSLAB®) is administered orally , in 1 daily dose.

Treatment groups

130 Participants
are divided into 2 treatment groups
Group A: Experimental groupExperimental treatment 1 intervention
Group B: Control groupPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Proportion of patients who experience a grade ≥2 peripheral neuropathy

Oxaliplatin-specific scale of Levi \[min grade 0 (better)- max Grade 4 (worse)\] after 6 cycles for FOLFOX or 4 cycles for XELOX

Time frame
Around week 12 (+/- 7 days) after initiation of treatment

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: